Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL195598 | 0.85 | P2RY12 (0.53) | SMN1; SMN2ALDH1A1LMNAP2RY12CYP1A2 | |
| SCHEMBL13362646 | 0.85 | SMN1; SMN2 (0.42) | L3MBTL1SMN1; SMN2ALDH1A1GAAHSD17B10 | |
| SCHEMBL28459125 | 0.77 | CYP2C9 (0.55) | SMN1; SMN2ALDH1A1LMNACYP2C9CYP2C19 | |
| SCHEMBL2007912 | 0.73 | FBP1 (0.53) | SMN1; SMN2ALDH1A1LMNACYP2C9CYP2C19 | |
| SCHEMBL4700005 | 0.72 | SMN1; SMN2 (0.57) | SMN1; SMN2ALDH1A1GAAHSD17B10LMNA | |
| SCHEMBL5931062 | 0.72 | LMNA (0.64) | SMN1; SMN2ALDH1A1GAAHSD17B10LMNA | |
| SCHEMBL9575785 | 0.71 | LMNA (0.62) | SMN1; SMN2ALDH1A1GAAHSD17B10LMNA | |
| SCHEMBL12630271 | 0.70 | KMT2A (0.47) | L3MBTL1SMN1; SMN2ALDH1A1GAALMNA | |
| SCHEMBL10165528 | 0.70 | SMN1; SMN2 (0.60) | SMN1; SMN2ALDH1A1GAAHSD17B10LMNA | |
| SCHEMBL11851628 | 0.70 | GAA (0.49) | SMN1; SMN2ALDH1A1GAALMNAP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156620-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| CN-101031565-A | Substituted 2H-1, 3-benzoxazin-4 (3H) -ones | PORTOLA PHARM INC (US) | 2007-09-05 | — | — | CN | disclosed |
| EP-1812429-A2 | SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES | Portola Pharmaceuticals, Inc. (US) | 2007-08-01 | — | — | EP | disclosed |
| US-7205296-B2 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| WO-2006039212-A2 | SUBSTITUTED 2H-1,3-BENZOXAZIN-4(3H)-ONES | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| US-20060069093-A1 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156620-A1 | [4-(6-FLUORO-7-METHYLAMINO-2,4-DIOXO-1,4-DIHYDRO-2H-QUINAZOLIN-3-YL)-PHENYL]-5-CHLORO-THIOPHEN-2-YL-SULFONYLUREA SALTS, FORMS AND METHODS RELATED THERETO | P2RY1, P2RY6, P2RY4 | L3MBTL1 3849/4885SMN1; SMN2 2387/4885ALDH1A1 712/4885 |
| US-20060069093-A1 | Substituted 2H-1,3-benzoxazin-4(3H)-ones | TBXAS1, TBXA2R, SERPINC1 | L3MBTL1 1259/4885SMN1; SMN2 933/4885ALDH1A1 704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.